SA
AGN

Smithwood Advisers’s Allergan Inc AGN Stock Holding History

Smithwood Advisers’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-500,000
Closed -$84.6M – 48
2014
Q2 		$84.6M Buy
+500,000
New +$77.8M 6.04% 3

Other funds holding AGN

PSCM
Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Smithwood Advisers's AGN Position: Q3 2014 in Review

Smithwood Advisers sold out of Allergan Inc (AGN) in Q3 2014, closing a stake of 500,000 shares — an estimated $84.6M sold.

Smithwood Advisers first reported a position in AGN in Q2 2014 and held it in 1 quarter. The position peaked at $84.6M in Q2 2014. 749 funds tracked by Wall St. Rank hold AGN as of Q3 2014.

  • Smithwood Advisers reported no remaining Allergan Inc position as of Q3 2014 after selling out during the quarter.
  • Smithwood Advisers sold 500,000 Allergan Inc shares in Q3 2014, an estimated $84.6M.
  • Smithwood Advisers first reported a position in Allergan Inc in Q2 2014 and held it in 1 quarter.
  • Smithwood Advisers's Allergan Inc position peaked at $84.6M in Q2 2014.
  • 749 funds tracked by Wall St. Rank held Allergan Inc as of Q3 2014.

Based on Smithwood Advisers's 13F filing for Q3 2014, filed 14 Nov 2014.